Novavax to Host Conference Call to Discuss Third Quarter Financial and Operating Results on November 9, 2020

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, will report its Q3 2020 financial and operational results on November 9, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET on the same day. Interested parties can join via a domestic dial-in number (877) 212-6076 or international number (707) 287-9331, using passcode 8059421. The replay will be available from 7:30 p.m. ET on November 9 until November 16, 2020. Novavax is focused on developing vaccines for infectious diseases, including its COVID-19 vaccine candidate NVX-CoV2373.

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, November 9, 2020.

Conference call details are as follows:

Date:	November 9, 2020
Time:	4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:	(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:	8059421
Webcast:	www.novavax.com, “For Investors”/ “Events”

Conference call and webcast replay:

Dates:	Starting at 7:30 p.m. ET, November 9, 2020 until
	7:30 p.m. ET November 16, 2020
Dial-in number:	(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:	8059421
Webcast:	www.novavax.com, “For Investors”/ “Events”, until February 9, 2021

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is currently conducting multiple clinical trials for NVX-CoV2373, its vaccine candidate against the virus that causes COVID-19, including a pivotal Phase 3 clinical trial in the United Kingdom to evaluate the efficacy, safety and immunogenicity in individuals aged 18-84 years of age. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both candidate vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

FAQ

When will Novavax report its Q3 2020 results?

Novavax will report its Q3 2020 financial results on November 9, 2020.

What time is the Novavax conference call on November 9, 2020?

The Novavax conference call is scheduled for 4:30 p.m. ET on November 9, 2020.

How can I access the Novavax conference call?

You can access the Novavax conference call at (877) 212-6076 for domestic calls or (707) 287-9331 for international calls.

What is the passcode for the Novavax conference call?

The passcode for the Novavax conference call is 8059421.

When will the Novavax conference call replay be available?

The replay of the Novavax conference call will be available starting at 7:30 p.m. ET on November 9 until November 16, 2020.

Where can I find more information on Novavax?

More information about Novavax can be found on their website at www.novavax.com.